Key Takeaways
- Revealis targets a new mechanism of cancer immunotherapy resistance rather than conventional tumor antigens.
- Initial studies show promising immune responses, but clinical efficacy data remains limited.
- The company aims to expand vaccine development to include multiple TEIPP peptides with support from Oncode Accelerator.
Innovative Approach to Cancer Immunotherapy
Revealis is pioneering a novel approach to cancer immunotherapy by focusing on a mechanism of resistance that allows tumors to evade effective immune responses. Unlike traditional therapeutic vaccines that target specific tumor antigens, Revealis aims to combat the cancer cells that escape immune pressure. This strategy complements existing therapies, such as checkpoint inhibitors, potentially offering a more effective treatment option.
Cancer cells often evade T-cell detection by disrupting their antigen-processing capabilities. Specifically, they can reduce the activity of Transporter Associated with Antigen Processing (TAP) proteins, which are crucial for presenting tumor antigens to the immune system. Research conducted by Leiden University Medical Center and Oncode Institute identified alternative antigens known as TEIPPs (T-cell epitopes associated with impaired peptide processing). Revealis plans to train T cells to recognize these less immunogenic targets, providing a new pathway for immune activation.
In a Phase 1/2 clinical trial involving 26 patients with metastatic non-small cell lung cancer who had previously progressed on checkpoint inhibitors, a prototype vaccine called TEIPP24 showed potential. This vaccine, derived from a synthetic peptide linked to LRPAP1, was specifically designed for patients carrying the HLA-A*0201 antigen. Over 80% of evaluable participants generated TEIPP-specific immune responses.
However, the immune activation has not yet resulted in strong efficacy data. Of the 24 participants who could be radiologically evaluated, only one achieved a partial response, while eight had stable disease, and two displayed mixed outcomes. The median progression-free survival for patients was 2.1 months, and most enrolled patients, 25 out of 26, experienced disease progression during follow-up. The trial primarily focused on assessing safety and immunogenicity rather than overall efficacy.
Looking ahead, Revealis plans to develop a more sophisticated vaccine that incorporates multiple TEIPP peptides, rather than relying on a single antigen. This effort is supported by the Oncode Accelerator, a Dutch consortium aimed at expediting cancer drug development while minimizing risks. The inclusion of a broader range of antigens could enhance immune responses and reduce patient eligibility restrictions present in the prototype vaccine.
Additionally, Revealis has secured undisclosed pre-seed funding from Oncode BV and other investors, although specific details regarding the funding amount and investor identities remain unknown. The company acknowledges the need for further financing and partnerships to advance its clinical development.
Emerging in a revitalized landscape for cancer vaccines, Revealis aims to differentiate itself by targeting shared vulnerabilities present in tumors that alter their antigen-presentation processes, distinguishing its approach from personalized therapies developed by other companies like Moderna and MSD. If successful, this strategy could redefine how immune escape is addressed in cancer treatment.
The content above is a summary. For more details, see the source article.